B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide

Ítems similars

• Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
  per: Venhoff, Nils, et al.
  Publicat: (2012)
• Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
  per: Stone, John H., et al.
  Publicat: (2010)
• CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
  per: Zeisbrich, Markus, et al.
  Publicat: (2021)
• Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement
  per: Geetha, Duvuru, et al.
  Publicat: (2015)
• Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
  per: Cortazar, Frank B., et al.
  Publicat: (2017)